JP2011121944A - ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー - Google Patents

ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー Download PDF

Info

Publication number
JP2011121944A
JP2011121944A JP2010273484A JP2010273484A JP2011121944A JP 2011121944 A JP2011121944 A JP 2011121944A JP 2010273484 A JP2010273484 A JP 2010273484A JP 2010273484 A JP2010273484 A JP 2010273484A JP 2011121944 A JP2011121944 A JP 2011121944A
Authority
JP
Japan
Prior art keywords
pik3ca
pten
mutation
subject
pi3k
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010273484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011121944A5 (enExample
Inventor
Anna Berkenblit
バーケンブリット アナ
Christina Marie Coughlin
マリエ コグリン クリスティナ
Jay Marshall Feingold
マーシャル ファインゴールド ジェイ
Daniel Stephen Johnston
ステファン ジョンストン ダニエル
Andrew Louis Strahs
ルイス ストラフス アンドリュー
Charles Michael Zacharchuk
マイケル ザチャーチャック チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2011121944A publication Critical patent/JP2011121944A/ja
Publication of JP2011121944A5 publication Critical patent/JP2011121944A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G01N33/57515—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010273484A 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー Withdrawn JP2011121944A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28582109P 2009-12-11 2009-12-11
US61/285,821 2009-12-11
US28787209P 2009-12-18 2009-12-18
US61/287,872 2009-12-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015051863A Division JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Publications (2)

Publication Number Publication Date
JP2011121944A true JP2011121944A (ja) 2011-06-23
JP2011121944A5 JP2011121944A5 (enExample) 2014-01-30

Family

ID=43628745

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010273484A Withdrawn JP2011121944A (ja) 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2016120503A Withdrawn JP2016169229A (ja) 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2016120503A Withdrawn JP2016169229A (ja) 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Country Status (5)

Country Link
US (4) US20130189274A1 (enExample)
EP (2) EP2510121A1 (enExample)
JP (7) JP2011121944A (enExample)
CA (1) CA2783743C (enExample)
WO (1) WO2011070499A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010494A (zh) * 2011-07-28 2014-08-27 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
JP2016188211A (ja) * 2012-06-08 2016-11-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の処置用のホスホイノシチド３キナーゼ阻害化合物と化学療法剤との変異体選択性及び組み合わせ

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
ES2729677T3 (es) 2009-11-09 2019-11-05 Wyeth Llc Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
AU2016265844B2 (en) 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
KR20190054826A (ko) * 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
AU2019340366B2 (en) * 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
IT201800010730A1 (it) * 2018-11-30 2020-05-30 Univ Degli Studi Milano Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia
CA3127686A1 (en) 2019-02-06 2020-08-13 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
JP5336174B2 (ja) * 2005-03-09 2013-11-06 アボット・ラボラトリーズ トラスツズマブによる治療の候補患者を確認するための診断方法
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY OF SENSITIVITY OF A TUMOR AGAINST A MTOR INHIBITOR
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
CA2683559C (en) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BREAST CANCER RESEARCH, vol. 7, no. 5, JPN6014053469, 2005, pages 609 - 616, ISSN: 0002967858 *
CANCER CELL, vol. 12, no. 4, JPN6014053467, 2007, pages 395 - 402, ISSN: 0002967856 *
CLIN CANCER RES, vol. 15, no. 7, JPN6014053471, 1 April 2009 (2009-04-01), pages 2552 - 2558, ISSN: 0002967857 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104010494A (zh) * 2011-07-28 2014-08-27 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
JP2016188211A (ja) * 2012-06-08 2016-11-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の処置用のホスホイノシチド３キナーゼ阻害化合物と化学療法剤との変異体選択性及び組み合わせ

Also Published As

Publication number Publication date
US20190271047A1 (en) 2019-09-05
US20130189274A1 (en) 2013-07-25
JP2020169212A (ja) 2020-10-15
JP2019052187A (ja) 2019-04-04
EP2510121A1 (en) 2012-10-17
US20220170107A1 (en) 2022-06-02
JP2015110669A (ja) 2015-06-18
JP2022022296A (ja) 2022-02-03
CA2783743C (en) 2022-10-04
WO2011070499A1 (en) 2011-06-16
CA2783743A1 (en) 2011-06-16
EP3575413A1 (en) 2019-12-04
JP2016169229A (ja) 2016-09-23
JP2017101072A (ja) 2017-06-08
US20160222467A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
CA2783743C (en) Phosphatidylinositol-3-kinase pathway biomarkers
Di Nicolantonio et al. Precision oncology in metastatic colorectal cancer—from biology to medicine
M Dillon et al. Therapeutic targeting of cancers with loss of PTEN function
Kim et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Le Du et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Tamborini et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Gombos et al. Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
EP2908132A2 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
CN103221825A (zh) 生物标志物和治疗方法
US20140221372A1 (en) Method of administration and treatment
CN103930111A (zh) 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
KR20170005419A (ko) Pi3k 억제제 피크틸리시브로 pr-양성 내강 a형 유방암을 치료하는 방법
Coughlin et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy
Osei et al. A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
JP2023507751A (ja) 膵臓がんの治療および予後
HK40018329A (en) Phosphatidylinositol-3-kinase pathway biomarkers
Hinz et al. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma
US9903867B2 (en) Methods for predicting and improving the survival of colorectal cancer patients
Miyamoto et al. Molecular landscape and treatment options for patients with metastatic colorectal cancer
Pender et al. Understanding lung cancer molecular subtypes
Wisniewski et al. Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growth
Stewart Modeling targeted therapy mechanisms and predictive biomarker discovery using human primary non-small cell lung cancer xenografts
HK1263276A1 (en) Method for selecting a therapy for the treatment of colorectal cancer patients
Zhang et al. AACR-IASLC JOINT CONFERENCE ON MOLECULAR ORIGINS OF LUNG CANCER: BIOLOGY, THERAPY, AND PERSONALIZED MEDICINE
Ebi et al. Oncogenic driver mutations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111129

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20111201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141216

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150421